CTIS Clinical Trial Applications in 2026: Sponsor Readiness and Lifecycle Management

CTIS and CTR: the correct starting point for 2026

The Clinical Trials Regulation, Regulation (EU) No 536/2014, provides the EU/EEA trial framework; CTIS is the information system supporting applications and oversight within it. CTIS has been mandatory for new applications since 31 January 2023. The transition period for ongoing trials authorised under the previous directive ended on 31 January 2025. Do not base a 2026 plan on an assumption that a general transition entitlement remains available.

EMA operates CTIS, while EU/EEA countries are responsible for trial authorisation and supervision. Sending a dossier through the system does not mean a trial has been authorised or sites can begin enrolling participants. Record submission, assessment, decision and operational site activation as separate internal statuses.

Create the sponsor readiness package before submission

The first meeting should produce more than a target submission date. Record the governing protocol version, countries in scope, document owners and independent reviewers. A document that appears ready is not necessarily consistent with the others. One control table for protocol version, product name, dose schedule and study title can reduce rework.

• Check organisation and user access, handover arrangements and deputies before submission.
• Retain document name, language, country, version, date, owner and review status in the inventory.
• Separate preparation, review, submission and response responsibilities between sponsor, CRO and local teams.
• Show which deliverable an absent document blocks and whose decision is pending.

Plan the Part I and Part II dossiers together

CTR assessment includes Part I and Part II components. Manage the shared scientific and technical dossier and country-level requirements with separate owners rather than reducing them to one undifferentiated document list. Part I-only submission is an option covered by specific EMA training material; it does not eliminate Part II requirements. Evaluate the pathway against the study's country plan and current rules.

A practical review method is to mark each dossier item as shared, country-specific or site-related. Once a translation is complete, review more than linguistic quality: check agreement between the protocol version, visit schedule and participant information. Decide beforehand which documents need reassessment when a country is added or the scope changes.

Manage requests for information in one response queue

CTIS supports tracking requests for information and their deadlines. Create a separate internal action for each question, linking its complete wording, scope, response owner, required document and reviewer. A general 'responses being prepared' status can hide dependencies until the final day.

• Use the system deadline as the governing date and set an earlier internal review deadline.
• Recheck affected files if a response changes the protocol or another document.
• Retain the submitted response and final document versions under the same record; distinguish email attachments from portal versions.

Prepare documents for publication before the final day

Revised CTIS transparency rules have applied since 18 June 2024. Consider public access alongside protection of personal data and commercially confidential information. The dossier plan should identify the owner and review step for publication versions. Renaming a file or covering visible text does not by itself establish a safe publication copy.

As an editorial review recommendation, inspect comments, tracked changes, document properties and attachments. Record what information was removed and why. Ask a second person to confirm that confidentiality review has not altered clinical meaning. Apply current CTIS disclosure rules by document type rather than relying on a general confidentiality label.

Track the 2026 ASR update and work after the application

EMA's sponsor guidance dated 24 September 2026 describes the new Safety tab and annual safety report workflow for October 2026. Before submitting an ASR, verify the workflow available in production, user roles and the current transition announcement. Distinguish a new report from one already being assessed through the previous workflow; this guide does not guarantee a particular activation day.

Assign owners for study milestones, applicable modifications, safety activities and results reporting in the post-submission calendar. An internal portal can track these activities without replacing actions required in the official system. Linking each completed action to the official submission or decision evidence helps the sponsor assess status.

Frequently asked questions

Does a CTIS submission mean EMA has approved the trial?

No. CTIS is the application and information system operated by EMA. Authorisation and supervision of the trial are responsibilities of the relevant EU/EEA countries.

Does the general transition period for directive trials continue in 2026?

No. The general transition period ended on 31 January 2025. Assess study-specific circumstances against current authority guidance.

Does a Part I-only application make Part II unnecessary?

No. This option does not remove Part II requirements. Check the chosen pathway and subsequent steps against current CTR and CTIS guidance.

Sources

1. EMA — Clinical Trials Regulation and transition dates
2. EMA — Clinical Trials Regulation becomes fully applicable, 31 January 2025
3. EMA — CTIS functions and transparency rules
4. EMA — CTIS Sponsor Handbook, version dated 7 July 2026 at source review
5. EMA — Part I-only applications and Part II requirements in CTIS
6. EMA — Revised CTIS Transparency Rules
7. EMA — Sponsor Guidance: New Safety Module on the Annual Safety Report, 24 September 2026
8. EUR-Lex — Regulation (EU) No 536/2014